Who are Cartesian Therapeutics, Inc.'s main suppliers?

Cartesian Therapeutics, Inc. (RNAC) key suppliers include: SHENYANG-SUNSHINE-PHARMACEUTICAL-CO-LTD, Artiva Biotherapeutics, Inc., Caribou Biosciences, Inc., Fate Therapeutics, Inc., Vor Biopharma Inc.. View the full supplier network at chainsifter.com/chain/RNAC.

Who are Cartesian Therapeutics, Inc.'s major customers?

Cartesian Therapeutics, Inc. (RNAC) key customers include: Caribou Biosciences, Inc., Fate Therapeutics, Inc., Kyverna Therapeutics, Inc., Biogen Inc., BIOGEN-MA-INC and 3 more. View the full customer network at chainsifter.com/chain/RNAC.

What sector is Cartesian Therapeutics, Inc. in?

Cartesian Therapeutics, Inc. (RNAC) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Cartesian Therapeutics, Inc. Supplier List (RNAC): 5 Verified Suppliers

5Suppliers

8Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Cartesian Therapeutics, Inc. (RNAC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships

1Distinct source URLs

5High confidence

0.745Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Cartesian Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
SHENYANG-SUNSHINE-PHARMACEUTICAL-CO-LTD	SHENYANG-SUNSHINE-PHARMACEUTICAL-CO-LTD	92%	The Company has paid to 3SBio an aggregate of $ 7.0 million in upfront and milestone-based payments under the 3SBio License as of March 31, 2026.
ARTV	Artiva Biotherapeutics, Inc.	72%	Reciprocal relationship from ARTV graph: uture environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or …
CRBU	Caribou Biosciences, Inc.	72%	Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of th…
VOR	Vor Biopharma Inc.	72%	Reciprocal relationship from VOR graph: focused sales, marketing and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product cand…

Cartesian Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
CRBU	Caribou Biosciences, Inc.	72%	Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c…
FATE	Fate Therapeutics, Inc.	72%	Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely…
KYTX	Kyverna Therapeutics, Inc.	72%	Reciprocal relationship from KYTX graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other agains…
BIIB	Biogen Inc.	62%	Reciprocal relationship from BIIB graph: Reciprocal relationship from RNAC graph: ns from June 2025 through May 2026. The funding was provided by NINDS to further the Company’s use of RNA-based CAR-T…
BIOGEN-MA-INC	BIOGEN-MA-INC	62%	r product development or future commercialization efforts. We will need to generate significant revenues to achieve profitability, and we may never do so. We believe that our existing cash, cash equi…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	the Sales Agreement, with Leerink Partners LLC to sell shares of the Company’s common stock, from time to time, through an “at the market” equity offering program under which Leerink Partners LLC act…
LICENSE-AGREEMENTS-BIOGEN-MA-INC	LICENSE-AGREEMENTS-BIOGEN-MA-INC	62%	ns from June 2025 through May 2026. The funding was provided by NINDS to further the Company’s use of RNA-based CAR-T cells to combat autoantibody-associated autoimmune disorders. Grant funding is to…
SHENYANG-SUNSHINE-PHARMACEUTICAL-CO-LTD	SHENYANG-SUNSHINE-PHARMACEUTICAL-CO-LTD	62%	the Sales Agreement, with Leerink Partners LLC to sell shares of the Company’s common stock, from time to time, through an “at the market” equity offering program under which Leerink Partners LLC act…

Cartesian Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
RNAC-DEBT-12242	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2016-12-31.
RNAC-DEBT-12241	Warrants outstanding: 196850	90%	xbrl warrant detail from xbrl 2026-03-31.
RNAC-DEBT	Debt stack $52.9M	90%	Market cache reports total debt of $52.9M.

Cartesian Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cartesian Therapeutics, Inc..

Cartesian Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
RNAC-OWNER-SQUAREPOINT-OPS-LLC	Squarepoint Ops LLC	90%	13F overlay lists Squarepoint Ops LLC as top holder; 83 tracked holders.

Cartesian Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
LYEL	Lyell Immunopharma, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
IPSC	Century Therapeutics, Inc.	100.00	2
JBIO	Jade Biosciences, Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
MYGN	Myriad Genetics, Inc.	100.00	2
BIIB	Biogen Inc.	100.00	1	['customer']
AUTL	Autolus Therapeutics plc	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
FATE	Fate Therapeutics, Inc.	100.00	1	['customer', 'supplier']
SNYNF	Sanofi	100.00	2
KYTX	Kyverna Therapeutics, Inc.	100.00	2	['customer']
NVSEF	Novartis AG	100.00	2
GRFS	Grifols, S.A.	100.00	2
JNJ	Johnson & Johnson	100.00	2
CRBU	Caribou Biosciences, Inc.	100.00	2	['customer', 'supplier']
EISAI	EISAI	50.00	2
CCCC	C4 Therapeutics, Inc.	50.00	2
CGEM	Cullinan Therapeutics, Inc.	50.00	2
SUPN	Supernus Pharmaceuticals, Inc.	50.00	2

Cartesian Therapeutics, Inc. Supply Chain